pSivida directors take up entitlements under rights issue

Directors of Perth headquartered global bio-nanotech company pSivida Ltd have confirmed that they will be taking up rights to subscribe for pSivida shares under their respective individual eligible entitlements to raise approximately $29 million.

Capital raised from this rights issue will primarily fund the phase III clinical trials of Medidur for the treatment of Diabetic Macular Edema, and phase IIa clinical trials of our lead BioSilicon product, BrachySil which is being developed for the treatment of inoperable pancreatic cancer.

The rights issue is on a non-renounceable 1 for 8 basis to raise approximately $29 million at 60 cents per ordinary share, and has an incorporated top up facility whereby eligible shareholders may apply for additional new ordinary shares in excess of their entitlement at the same price.

The rights issue is not underwritten. The record date for the rights issue was 22 May 2006.


(existing subscribers)

The password field is case sensitive.
Request new password

Register for free

(first time users)
FREE: 8 articles per month + twice daily business email alerts



Rio Tinto$21.40bn
BHP Billiton Iron Ore$17.97bn
North West Shelf Venture$16.84bn
Fortescue Metals Group$8.12bn
Gold Corporation$5.81bn
CF 2011
CF Q3 FY12
Elizabeth Quay
IBM Tech Staff
Subiaco Revenue
R&D Expenditure
Online Revenue
Female Uni Chancellors
Executive Salary 2012
Employment growth
Population growth
WA employment figure
WA GST return
Business Credit growth
Green Star Certified
SMEs Social Media use
Perth's Median house price
China investment in WA
China GDP growth
Education Revolution allocation
Indigenous resource workers

Feedback Form